IGF-1; growth factor; brain Insulin-like growth factor 1 (IGF-1) is a pluripotent growth factor, with multiple functions in the peripheral and central nervous systems. Increasing evidence suggests that IGF-1 fine-tunes the development of the central nervous system, ensuring proper neuronal differentiation, maturation, and connectivity. It supports neuronal survival and axon growth, and acts on myelinating Schwann cells and oligodendroglia. The biological functions of IGF-1 are modulated by the IGF-1 signaling pathway. Recent studies have proposed the modulation of the members of the IGF-1/IGF-1 signaling pathway as treatment for neuropathologies. In this study, we introduce the structure of IGF-1/2 and its receptors, with the intra-cellular interactions. Further, we review the therapeutic effects of IGF-1 in different models of brain diseases, via activation of different cellular mechanisms.
Introduction
The growth and development of neuronal cells of the central nervous system (CNS) are regulated and specified by multiple neural signals and their interactions. In the recent years, accumulating experimental data have proved that the neurotrophic factor, insulinlike growth factor-1 (IGF-1), is essential for the normal development and growth of the brain. The structure of IGF-1 includes a single chain of 70 amino acids with a molecular weight of 7649 Da. Importantly, IGF-1 is abundant during embryonic development, but its expression decreases during postnatal life. In vivo, IGF-1 is mainly produced in the liver of adults, regulated by the growth hormone (GH) [1] .
The IGF-1 has an important role in the development of the CNS and tissue injury. As a type of insulin, IGF-1 performs multiple functions, regulating different cellular processes depending on a variety of factors including its concentration, the cell type, and the developmental period of the animal. On the other hand, IGF-1 levels vary depending on the developmental stage. The developmental stage of the brain determines the spatial and temporal expression of IGF-1 in the CNS. Moreover, IGF-1 may be distributed abundantly in an endocrine, paracrine, or autocrine manner [2, 3] . Mechanistically, IGF-1 controls adult neurogenesis not only by regulating the number and differentiation of stem cells, but also by influencing the position and migration of mature neural cells. More studies on the expression, regulation, and function of IGF-1 are needed to understand and treat neuro-developmental disorders.
The structure of insulin-like growth factor 1/and receptors
The IGF-1 belongs to a superfamily, which consists of insulin, IGF-1, and IGF-2, all of which have similar physical structure. However, these neurotrophic factors perform different functions in the brain by binding to different receptors (Figure 1) . The IGF-1R is a tetrameric tyrosine kinase receptor, composed of two α subunits and two β subunits [4, 5] . The majority of IGF-1s form a ternary complex with IGF-1R and an acid-labile subunit (ALS) [6] . There is a cAMP response element (CRE) in the 5′ regulatory region of the IGF1 gene [7, 8] . The cAMP may promote the expression of IGF1 in the microglial cells; thus, the CRE controls the IGF1 expression in some cases. The proinflammatory mediators may affect the neurotrophic factor IGF-1 partly by activating the 5′ regulatory region. Therefore, there is a close association between neural environment, growth factor production, and neuroinflammation [9, 10] . An important factor in the CNS, IGF-1 is involved in normal cognitive function and development [11] [12] [13] [14] . The IGF-1 belongs to the IGF family of proteins, including the receptors IGF-1R and IGF-2R, and several IGF-binding proteins (IGFBPs) [3, 15, 16] . Of the ten IGFBPs produced in humans, only IGFBPs 1-6 have a high affinity for IGF-1, and only IGFBP-3 and IGFBP-5 demonstrate the structural domains necessary to bind ALS and form the ternary complex [17] [18] [19] . However, since the IGFBPs have distinct but overlapping functions, the significance of their distribution and activation pattern remains unclear. The expression of IGF-1R, including the βgc (an immunochemically distinct β subunit of IGF-1R) containing variant, is involved in the regeneration of CNS axons [20, 21] . In the CNS, microglia and macrophages are the main sources of autocrine IGF-1. The IGF-1 mRNA is mainly expressed by the mesenchymal cells in parts of the CNS such as the hippocampus, cerebellum, and spinal cord [22] [23] [24] . Besides, experimental studies have reported that microglia and astrocytes express IGF-1 [25] [26] [27] [28] . Less information is available on IGF-2, but there are reports that show expression of IGF-2 in microglia of the developing and injured CNS [29] [30] [31] .
Both IGF-1 and IGF-2 may promote the growth and development of the CNS by binding to the IGF-1R. On the other hand, IGF-2R does not act as a signaling receptor, but participates in the capture and degradation of extracellular IGF-2 (and IGF-1) [32] . Although serum IGF-1 and IGF-2 levels exert protective effects on neurogenesis and neuronal survival [3, 13, 33] , autocrine or intrathecally derived IGF-1 plays a significant role in maintaining normal brain function [34] .
In human beings, the IGF-2 expression is maintained at a constant level after birth. As described above, IGF-2 promotes cell survival, growth, and metabolism through IGF-1R, not IGF-2R. There is evidence that decreased IGF-1 levels result in impaired cognitive function and neurodegeneration. In patients with Alzheimer's disease (AD), studies have demonstrated a significant negative correlation with the IGF-1 and serum TNF-α levels; IGF-1, therefore, leads to impaired cognition by increasing serum TNF-α. Further, in motor neuron disease, the levels of IGF-1 in the cerebrospinal fluid (but not serum) were found to be decreased [35] . Recent studies have established that exogenous IGF-1 may reduce the inflammatory response of rat astrocytes [36] . However, there are very few studies on the physiological function of IGF-2 in the nervous system.
The IGF-1 is considered an important neurotrophic factor. However, IGF family and the receptors perform their various physiological roles by the separate pathways, and bind to different cells with identical outcomes (Figure 1) . Interestingly, IGF-1 activation leads to different effects in different organs. We believe that studying the physiology of the CNS may help us understand the physiological mechanisms underlying the effects of IGF-1. In fact, there is a rare cell line which is not affected by the IGF family. As described above, most tissues secrete IGF-1, with the liver contributing around 70% of the total circulating IGF-1, as determined by genetic deletion of the hepatic gene [37] . Generating a model for IGF-1 deficiency in the CNS is more difficult compared to the case for the liver or the kidney. The expression of IGF-1 is temporally regulated in the brain, unlike that in the other organs. However, during development, there is a high level of IGF-1 in the brain.
Connections between different signaling pathways and substrates
The biological effects of IGF-1 are mediated by its binding to the IGF-1R which activates the two major intracellular signals: phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway and the mitogen-activated protein kinase (MAPK) pathway [38] . As many neurotransmitters (such as norepinephrine and dopamine) activate the cAMP/protein kinase A (PKA) pathway, these results suggest that IGF-1 expression may be triggered in a neural environment.
In mammals, the IGF-1/IGF-1R signal activates distinct receptors, while a single receptor is activated by multiple ligands in invertebrates. The IGF-1Rs are members of the tyrosine kinase receptor family that are structurally formed by two α-subunits and two β-subunits. The α-β half of the receptor homodimerizes which leads to the stepwise phosphorylation and activation of MEK1/MEK2 and ERK1/ERK2. Activated ERK1/2 phosphorylates many cellular and nuclear substrates, inducing the survival and differentiation of cells. In addition, IGF-1 receptors bound to a ligand can be directed to the nucleus to act as transcriptional modulators. In the PI3K/Akt pathway, activated PI3K generates the second messenger, which is the key step for negative regulation of the PI3K/Akt signaling cascade performed by phospholipid phosphatases such as PTEN.
Activated Akt phosphorylates many targets, including the FoxO transcription factor family and members of the mTOR signaling pathway, reducing the transcription of its targets, including genes involved in oxidative stress responses, cell maintenance, and autophagy. The but may also heterodimerize, cooperatively bound by the hormones. The binding of IGF-1 to the IGF-1R stimulates the Son of Sevenless (SOS) and the adapter protein Grb2, inducing the GDP-bound Ras to active GTP-bound Ras, triggering the activation of MAPK [39] (Figure 1) . The MAPK phosphorylates and activates extracellular signal-regulated kinase (ERK), inducing transcription and proliferation of multiple cell types [3, [40] [41] [42] [43] . The signals are, in turn, activated by the phosphorylation of the substrates [3, 5, 40, 44] . The PI3K phosphorylates Akt, while phospho-Akt promotes myriad downstream kinase-phosphatase branches [3, 16] . The mechanistic target of rapamycin (mTOR) is the catalytic subunit of two distinct complexes-mTORC1 and mTORC2. The mTOR acts as the Akt substrate, activating p70 ribosomal protein S6 kinase (p70S6K), while mTORC2 activates a series of kinases (including Akt). The mTORC2 affects protein translation and autophagy [3, [45] [46] [47] [48] [49] , while mTORC1 regulates lipid synthesis, glucose metabolism, and mitochondrial function [50, 51] .
The activation of Akt also leads to the activation of forkhead box protein O (FOXO), regulating oxidative stress and apoptosis [3, 40, 52] . Moreover, Akt can activate the cAMP responsive element binding protein, regulating the transcription of genes involved in cell cycle progression, survival, and differentiation. Importantly, multiple levels of cross-talk exist between the PI3K/ Akt and MAPK signaling pathways [53] . However, in retinal ganglion cells, ERK and Akt are activated independently, and there is no direct interaction between these two survival signals [54] .
The activation of IGF-1 can also reduce the production of pro-inflammatory cytokines through suppression of the nuclear factor kappa-light-chainenhancer of activated B cells signaling pathway, thus, inhibiting the cascade of pro-inflammatory cytokines [55] . With the overexpression of IGF-1, the levels of the pro-inflammatory cytokines, TNF-α and IL-1ß, were considerably reduced [56] . Another study showed that IGF signaling can interact with canonical Wnt-catenin signaling to promote the proliferation of neural precursors in vivo [57] . Further, IGF-1 signaling is capable of interacting with Wnt-c-Jun N-terminal kinase signaling in Xenopus sp. embryos [58] . On decreasing the IGF-1 or IGF-1R level, the level of phospho-glycogen synthase kinase3β (GSK3β, an enzyme known to regulate β-catenin stability) and the expression of β-catenin (a key member of the canonical Wnt signal pathway) reduces, at both mRNA and protein levels [57, 59] . Furthermore, increasing β-catenin abundance by suppressing phospho-GSK3β activity drastically reduces the detrimental effects of IGF-1R deficiency on neural growth.
Protection of IGF-1 after traumatic brain injury
Traumatic brain injury (TBI) is accompanied by morbidity or neuronal death in the hippocampus, a vital region for cognitive function. In the hippocampus, immature neurons are particularly susceptible to TBI. Treatment strategies that protect immature neurons or improve post-traumatic neurogenesis in the hippocampus may be significant for promoting functional recovery following TBI. During development, new neurons are generated in the subventricular zone, the olfactory bulb, the hippocampus, and the cerebellum of human and rodent brains. Newly formed neurons participate in normal cognitive function and depletion of these immature neurons result in deficits in learning and memory. Following TBI, only a small portion of neurons capable of regeneration survive and differentiate into mature neurons that are functionally incorporated into the cognitive processes. Enhancement of post-traumatic neurogenesis is a promising approach to improve learning and memory following TBI. Recent studies have showed that IGF-1 overexpression enhances the formation of new neurons, without depleting the neural stem cell pool, within 10 days of brain injury, increasing the density and dendritic arborization of hippocampal immature neurons. This delayed increase appears to be driven by enhanced neuronal differentiation, rather than increased cellular proliferation [60] . Transplantation of exogenous neurons in the injured CNS, or inducing the growth, proliferation, and differentiation of endogenous neurons may be one potential therapeutic approach against TBI [61] . There are a small number of neural stem cells (NSCs) in the adult brain, and hardly any of these differentiate to neurons under normal conditions. Neurotrophic factors, however, can promote the differentiation of NSCs into neurons.
The IGF-1 has a very short half-life period of approximately 12 hours [62, 63] . Therefore, multiple sources would be required to maintain a therapeutically relevant level to elicit its trophic effects. There is a need for a cell-based system that provides sustained delivery of IGF-1 [56] . Neural progenitor cells are able to differentiate into a specific cell type and protect other cells by secreting neurotrophic factors. Human neuronal progenitor cells could be stably transfected to express sustained levels of biologically active IGF-1.
Retinal neuronal progenitor cells have proved effective in the direct replacement of lost cells or enhancing cell-survival after injury by paracrine or neurotrophic factors. These findings provide experimental evidence, and form the basis for applying cell-based strategies, for local delivery of neurotrophic factors. Recently, Zhang et al. proved that IGF-1 promoted Brn-4 expression and differentiation of NSCs via the PI3K/Akt pathway [64] . The cells differentiated from the NSCs were positive for the neuronal marker microtubuleassociated protein 2.
Protection of IGF-1 after ischemic brain injury
Cardiac arrest (CA) is one of the most significant causes of global brain ischemia [65] . Most patients have poor cerebral function after being discharged from the emergency room. The ischemic brain damage causing by CA is mainly restricted to the hippocampus. There are no therapeutic approaches against the behavioral and cognitive dysfunction resulting from the hippocampal damage, accompanied by memory loss, emotion change, persistent vegetative state, and even death in some cases [66] . Studies have shown that the hippocampal function and learning ability were improved in neonatal rats with hypoxic ischemic injury, due to the increased secretion of IGF-1, after adipose tissue derived stem cells were transplanted via the jugular vein. Moreover, the nerve injuries and cerebral infarction areas were reduced by increased secretion of IGF-1 upon transplantation of mesenchymal stem cells in the rat model of middle cerebral artery occlusion [67] . The levels of IGF1 mRNA have been reported to increase in local cerebral ischemia, and the increase was proportional to the extent of the brain injury. A study of a global brain ischemia model with blinded randomization of animals into treatment groups, and an intention-to-treat design and evaluation of the outcome at both the tissue and neurobehavioral levels, indicated that IGF-1 administration, with therapeutic hypothermia, initiated at the onset of reperfusion, confers a statistically significant degree of histologic and functional neuroprotection following global brain ischemia in healthy male rats after 28 days of reperfusion [68] .
Protection of IGF-1 in Alzheimer's disease
The world is currently facing a global AD pandemic, and there is an urgent necessity to find approaches that can halt, or even cure this disease [69] . Insulin signaling is emerging as an important factor in neurodegenerative processes, and aging in general. Both in vivo and in vitro studies have revealed the role of IGF-1R in the promotion of neuronal survival, synaptic plasticity, and alleviation of (amyloid-beta) Aβ toxicity [70] . Normal aging is associated with declining levels of IGF-1, and administration of insulin can improve cognitive function in patients with AD. Brains from patients with AD were found to be IGF-1-resistant [71] . Hong and Lee reported that IGF-1 could enhance the clearance of Aβ from the murine brain [72] . However, there are inconsistencies in the reports regarding the role of insulin signaling and its association with AD. Treatment of SH-SY5Y cells overexpressing the Swedish mutation of amyloid precursor protein with IGF-1 resulted in increased production of Aβ via a secretaseindependent mechanism [73] . Data on levels of IGF-1 in the cerebrospinal fluid of patients with AD, and the effects of IGF-1 treatment on AD pathology are somehow conflicting. The central insulin/IGF-1 signaling provides a plausible starting point for targetidentification and drug-development in AD. There is a need for further studies exploring the effect of increased serum IGF-1 levels to add new insights to this interesting discussion.
Conclusion
The effects of IGF-1 in the brain are disparate, making the physical mechanism more difficult to understand. For this reason, an understanding of the role of IGF-I would be extraordinarily helpful. New reports about the functions of IGF-1 in the human beings are being published lately. This peptide forms an intricate functional network with other members of the pathway, and cooperates with many other growth hormones. It influences cognitive function, and its key role in health and disease is now firmly established. Above all, IGF-1 is a master regulator of brain homeostasis, regulating neurogenesis and synaptogenesis in the brain. Further exploration of its roles in the brain may expand this view. The potential cooperative action of IGF-1/IGF-1 signaling pathways on cognitive function is an important aspect that requires further investigation, as most of the studies, to date, have emphasized distinct actions of insulin, IGF-1, and IGF-2 in the brain. The members of the IGF-1 signaling pathway show an evolutionary trend towards such cooperativity, probably due to the hybridization among them such as that of insulin with IGF-1Rs. However, this is speculative and needs to be confirmed by future research. Data from animal models have demonstrated the beneficial effects of the central insulin/IGF-1R signaling. However, further investigations on how the intranasal insulin/IGF-1 application confers protection against different diseases is needed.
